Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates Sells 28,680 Shares of Stock

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sharon Mates sold 28,680 shares of Intra-Cellular Therapies stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $74.46, for a total transaction of $2,135,512.80. Following the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $79,696,697.34. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Sharon Mates also recently made the following trade(s):

• On Wednesday, August 21st, Sharon Mates sold 53,013 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45.

Intra-Cellular Therapies Stock Performance

NASDAQ:ITCI opened at $74.48 on Friday. Intra-Cellular Therapies, Inc. has a one year low of $45.50 and a one year high of $84.89. The firm has a market cap of $7.86 billion, a P/E ratio of -64.21 and a beta of 1.01. The firm has a 50-day simple moving average of $75.06 and a 200-day simple moving average of $71.11.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.03. The firm had revenue of $161.40 million during the quarter, compared to analyst estimates of $157.74 million. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative return on equity of 18.49%. Intra-Cellular Therapies’s revenue was up 45.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.45) EPS. On average, research analysts predict that Intra-Cellular Therapies, Inc. will post -0.54 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ITCI. Canaccord Genuity Group boosted their price objective on shares of Intra-Cellular Therapies from $107.00 to $113.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. Mizuho boosted their price objective on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, June 21st. Royal Bank of Canada lowered their price objective on shares of Intra-Cellular Therapies from $107.00 to $106.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. The Goldman Sachs Group lowered their price objective on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Intra-Cellular Therapies from $79.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $97.00.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Kapitalo Investimentos Ltda bought a new position in shares of Intra-Cellular Therapies during the 4th quarter worth approximately $26,000. Headlands Technologies LLC bought a new position in shares of Intra-Cellular Therapies during the 1st quarter worth approximately $32,000. Signaturefd LLC raised its stake in shares of Intra-Cellular Therapies by 85.7% during the 4th quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 239 shares in the last quarter. Fidelis Capital Partners LLC bought a new position in shares of Intra-Cellular Therapies during the 1st quarter worth approximately $53,000. Finally, Summit Securities Group LLC bought a new position in shares of Intra-Cellular Therapies during the 2nd quarter worth approximately $56,000. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.